Basel, Switzerland, November 17, 2026
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) 150 mg for the treatment of adults with polymyalgia rheumatica (PMR) who have experienced an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering. With this regulatory milestone, Cosentyx becomes the first and only anti-interleukin-17 (anti-IL-17) biologic approved in the United States for people living with PMR. The approval marks the medicine’s 11th indication in the United States and represents an important advancement in the treatment of this inflammatory condition, which primarily affects adults over 50 years of age. The new indication provides an additional therapeutic option for patients who may face difficulties with prolonged corticosteroid treatment. Long-term steroid use can increase the risk of complications, including osteoporosis, cardiovascular disease and diabetes. The FDA decision expands the clinical application of Cosentyx and strengthens Novartis’ position in the immunology and inflammatory disease treatment market.
Cosentyx Offers a New Treatment Option for PMR Patients
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease commonly characterized by pain and stiffness in the shoulders, neck and hips. The condition can significantly affect daily activities, mobility and quality of life, particularly among older adults. Corticosteroids have traditionally been the standard treatment for PMR; however, disease relapses are common, and some patients experience difficulties when reducing their steroid doses. According to Novartis, approximately 966,000 people in the United States are living with PMR, highlighting the need for additional treatment options. Relapses can affect up to 40% of patients during the first year, while extended corticosteroid exposure may contribute to several health complications. Cosentyx works by directly inhibiting interleukin-17A (IL-17A), a cytokine involved in inflammatory immune responses. As a fully human monoclonal antibody, secukinumab blocks this inflammatory pathway and helps regulate immune-mediated inflammation. Its approval for PMR introduces a targeted biologic treatment option for eligible adults whose disease is not adequately controlled with corticosteroids or who cannot tolerate steroid tapering.
Phase III REPLENISH Trial Demonstrates Sustained Remission
The FDA approval is supported by findings from the pivotal Phase III REPLENISH clinical trial (NCT05767034), a global, multicenter, randomized, double-blind, placebo-controlled study conducted across 27 countries. The study evaluated the efficacy and safety of secukinumab in adults with PMR. Participants were assigned to receive Cosentyx 300 mg, Cosentyx 150 mg or placebo, alongside a 24-week corticosteroid tapering regimen. The trial successfully achieved its primary endpoint, demonstrating that patients receiving Cosentyx 150 mg achieved sustained remission at Week 52 at a rate of 40.5%, compared with 20.5% among patients receiving placebo. This represented approximately twice the sustained remission rate in the treatment group following corticosteroid tapering. The findings also demonstrated steroid-sparing benefits, supporting the potential of secukinumab to help patients reduce their reliance on prolonged corticosteroid treatment. The trial’s safety findings were generally consistent with the established safety profile of Cosentyx. However, hypersensitivity reactions and urinary tract infections occurred more frequently in the 150 mg treatment group than in the placebo group. Serious adverse events were reported in 15.9% of patients receiving Cosentyx 150 mg compared with 14.2% in the placebo group. These findings provide important clinical evidence supporting the medicine’s newly approved indication.
Novartis Expands Cosentyx Immunology Portfolio
The PMR approval further strengthens Novartis’ global immunology portfolio, building on more than a decade of clinical experience with Cosentyx across multiple immune-mediated inflammatory diseases. The medicine is already approved for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The addition of PMR as its 11th U.S. indication expands its therapeutic reach into another area of significant unmet medical need. The PMR indication has also received approval in the European Union, while additional regulatory reviews are ongoing in other markets, including Japan. Novartis has submitted the clinical data for regulatory assessment in Japan as part of its efforts to expand access to the treatment internationally. The REPLENISH clinical findings were previously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress and published in the New England Journal of Medicine. The FDA approval represents a significant milestone in the development of targeted treatments for inflammatory rheumatic diseases. By introducing an anti-IL-17 biologic option for eligible adults with PMR, Novartis aims to address limitations associated with conventional steroid-based treatment and advance individualized care for patients living with chronic inflammatory conditions.
Source: Novartis press release



